Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Charles River Laboratories International, Inc. (CRL) Analyst/Investor Day Transcript
Seeking Alpha9/24/2026Neutral
CRL
Charles River LaboratoriesNYSEHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$14.11B
P/E Ratio
—
EPS
$-4.80
Beta
1.41
52W High
$303.31
52W Low
$145.47
50-Day MA
$267.77
200-Day MA
$206.96
Dividend Yield
—
Profit Margin
-5.96%
Forward P/E
22.42
PEG Ratio
0.12
About Charles River Laboratories
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products and outsourcing services for research and development in the pharmaceutical industry and offer support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.
Fundamentals
| Revenue (TTM) | $4.00B |
| Gross Profit (TTM) | $1.38B |
| EBITDA | $849.12M |
| Operating Margin | 15.10% |
| Return on Equity | -7.52% |
| Return on Assets | 4.11% |
| Revenue/Share (TTM) | $81.86 |
| Book Value | $59.50 |
| Price-to-Book | 4.66 |
| Price-to-Sales (TTM) | 3.50 |
| EV/Revenue | 4.02 |
| EV/EBITDA | 72.91 |
| Quarterly Earnings Growth (YoY) | -17.30% |
| Quarterly Revenue Growth (YoY) | -2.70% |
| Shares Outstanding | $48.17M |
| Float | $47.22M |
| % Insiders | 0.47% |
| % Institutions | 123.67% |
Historical Volatility
HV 10-Day
41.00%
HV 20-Day
36.47%
HV 30-Day
33.74%
HV 60-Day
40.20%
HV Rank
16.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($296.64 target)
4
Strong Buy9
Buy2
Hold1
SellLatest News
PGNY vs. CRL: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research9/18/2026Neutral
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Seeking Alpha9/15/2026Neutral
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha9/14/2026Neutral
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Business Wire9/11/2026Neutral
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Zacks Investment Research9/1/2026Neutral
CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
Zacks Investment Research8/21/2026Positive
Charles River Gains 88.6% in a Year: What's Driving the Rally?
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
Zacks Investment Research8/21/2026Positive
How an Insider CEO Is Taking a Fresh Look at Charles River
WSJ8/20/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRL and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026